Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1773-1784

  Chang, Hsiang Lin ^a   Sugimoto, Yasuro ^a,b   Liu, Suling ^c   Ye, Weiping ^a   Wang, Li Shu ^a   Huang, Yi Wen ^a   Lin, Young C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; Estrogen receptor ; KGF; Progesterone receptor; Protein tyrosine phosphatase (PTP ); Tamoxifen resistance

Indexed keywords

ANDROGEN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYDROXYTAMOXIFEN; KERATINOCYTE GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR 13; PENTAPEPTIDE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE GAMMA; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR 7; HUMANS; NERVE TISSUE PROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 33745605543     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Clarke RB, Howell A, Potten CS and Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57(22): 4987-4991, 1997.
2. Leung G, Tsao SW and Wong YC: Sex hormone-induced mammary carcinogenesis in female Noble rats: detection of differentially expressed genes. Breast Cancer Res Treat 77(7): 49-63, 2003.
3. Kuiper GG and Brinkmann AO: Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol 100(1-2):103-107, 1994.
4. Diamond MI, Miner JN, Yoshinaga SK and Yamamoto KR: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249(4974): 1266-1272, 1990.
5. Kraus WL, McInerney EM and Katzenellenbogen BS: Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 92(26): 12314-12318, 1995.
6. Kumar V, Green S, Stack G, Berry M, Jin JR and Chambon P: Functional domains of the human estrogen receptor. Cell 51(6): 941-951, 1987.
7. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785): 71-85, 1992.
8. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18): 1371-1388, 1998.
9. Clarke R, Leonessa F and Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53(1): 25-71, 2001.
10. Conneely OM, Jericevic BM and Lydon JP: Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8(2): 205-214, 2003.
11. Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30): 7721-7735, 2005.
12. De Vivo I, Hankinson SE, Colditz GA and Hunter DJ: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 63(17): 5236-5238, 2003.
13. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB and Fuqua SA: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10(8): 2751-2760, 2004.
14. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3): 321-333, 2002.
15. Barnea G, Silvennoinen O, Shaanan B, Honegger AM, Canoll PD, D'Eustachio P, Morse B, Levy JB, Laforgia S, Huebner K et al: Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. Mol Cell Biol 13(3): 1497-1506, 1993.
16. Hayashi S, Sakamoto T, Inoue A, Yoshida N, Omoto Y and Yamaguchi Y: Estrogen and growth factor signaling pathway: basic approaches for clinical application. J Steroid Biochem Mol Biol 86(3-5): 433-442, 2003.
17. Marino M, Acconcia F and Trentalance A: Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 14(6): 2583-2591, 2003.
18. Martin MB and Stoica A: Insulin-like growth factor-I and estrogen interactions in breast cancer. J Nutr 132(12): 3799S-3801S, 2002.
19. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB and Stoica A: Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 22(14): 2073-2087, 2003.
20. Wong CW, McNally C, Nickbarg E, Komm BS and Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99(25): 14783-14788, 2002.
21. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165, 1992.
22. Miyamoto M, Naruo K, Seko C, Matsumoto S, Kondo T and Kurokawa T: Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property. Mol Cell Biol 13(7): 4251-4259, 1993.
23. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H and Matsumoto K: Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 89(19): 8928-8932, 1992.
24. Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cheon G, Taylor WG, Fortney E, Sakata H, Finch PW et al: Keratinocyte growth factor. Cell Biol Int 79(5): 399-411, 1995.
25. Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cunha GR and Finch PW: Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. Exs 74: 191-214, 1995.
26. Koos RD, Banks PK, Inkster SE, Yue W and Brodie AM: Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 45(4): 217-225, 1993.
27. Luqmani YA, Bansal GS, Mortimer C, Buluwela L and Coombes RC: Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur J Cancer 32A(3): 518-524, 1996.
28. Zhang Y, Sugimoto Y, Kulp SK, Farrar WB, Brueggemeier RW and Lin YC: Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells. Oncol Rep 5(3): 577-583, 1998.
29. Imagawa W, Cunha GR, Young P and Nandi S: Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. Biochem Biophys Res Commun 204(3): 1165-1169, 1994.
30. Pekonen F, Nyman T and Rutanen EM: Differential expression of keratinocyte growth factor and its receptor in the human uterus. Mol Cell Endocrinol 95(1-2): 43-49, 1993.
31. Ulich TR, Yi ES, Cardiff R, Yin S, Bikhazi N, Biltz R, Morris CF and Pierce GF: Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor. Am J Pathol 144(5): 862-868, 1994.
32. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM and Aaronson SA: Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 89(1): 246-250, 1992.
33. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D and Lonai P: Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158(2): 475-486, 1993.
34. Savagner P, Valles AM, Jouanneau J, Yamada KM and Thiery JP: Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 5(8): 851-862, 1994.
35. LaRochelle WJ, Dirsch OR, Finch PW, Cheon HG, May M, Marchese C, Pierce JH and Aaronson SA: Specific receptor detection by a functional keratinocyte growth factor-immunoglobulin chimera. J Cell Biol 129(2): 357-366, 1995.
36. Osslund TD, Syed R, Singer E, Hsu EW, Nybo R, Chen BL, Harvey T, Arakawa T, Narhi LO, Chirino A et al: Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor. Protein Sci 7(8): 1681-1690, 1998.
37. Okarvi SM: Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 24(3): 357-397, 2004.
38. Shock LP, Bare DJ, Klinz SG and Maness PF: Protein tyrosine phosphatases expressed in developing brain and retinal Muller glia. Brain Res Mol Brain Res 28(1): 110-116, 1995.
39. Gaits F, Li RY, Ragab A, Ragab-Thomas JM and Chap H: Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells. Biochem J 311(Pt 1): 97-103, 1995.
40. Klarlund JK: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 41(3): 707-717, 1985.
41. Kaplan R, Morse B, Huebner K, Croce C, Howk R, Ravera M, Ricca G, Jaye M and Schlessinger J: Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain. Proc Natl Acad Sci USA 87(18): 7000-7004, 1990.
42. Krueger NX, Streuli M and Saito H: Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J 9(10): 3241-3252, 1990.
43. Krueger NX and Saito H: A human transmembrane protein-tyrosine- phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc Natl Acad Sci USA 89(16): 7417-7421, 1992.
44. Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM, Huang JT, Cannizzaro LA, Park SH, Druck T et al: The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J Biol Chem 268(14): 10573-10581, 1993.
45. Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, McCue P, Druck T and Huebner K: Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res 54(14): 3710-3713, 1994.
46. van Niekerk CC and Poels LG: Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors. Cancer Lett 137(1): 61-73, 1999.
47. Liu S, Sugimoto Y, Sorio C, Tecchio C and Lin YC: Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. Oncogene 23(6): 1256-1262, 2004.
48. Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL and Lin YC: Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents. Breast Cancer Res Treat 71(1): 21-35, 2002.
49. Liu S, Sugimoto Y, Kulp SK, Jiang J, Chang HL, Park KY, Kashida Y and Lin YC: Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Res 22(6C): 3917-3923, 2002.
50. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A and Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10(24): 7895-7903, 1982.
51. Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19(14): 3998, 1991.
52. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A and Liu FF: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104(2): 195-203, 2003.
53. Cormier EM, Wolf MF and Jordan VC: Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 49(3): 576-580, 1989.
54. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95(2): 142-153, 2003.
55. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2): 101-112, 2002.
56. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE and Gee JM: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8(3): 175-182, 2001.
57. Schiff R, Massarweh S, Shou J and Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9(1 Pt 2): 447S-454S, 2003.
58. Cui X, Zhang P, Deng W, Osterreich S, Lu Y, Mills GB and Lee AV: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17(4): 575-588, 2003.
59. Liu S and Lin YC: Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17beta. Breast J 10(6): 514-521, 2004.
60. Freiss G and Vignon F: Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 8(10): 1389-1396, 1994.
61. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A and Auricchio F: Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 18(9): 2500-2510, 1999.
62. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E and Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6): 1292-1300, 1996.
63. Migliaccio A, Pagano M and Auricchio F: Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 8(8): 2183-2191, 1993.
64. Taniguchi F, Harada T, Sakamoto Y, Yamauchi N, Yoshida S, Iwabe T and Terakawa N: Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 88(2): 773-780, 2003.
65. Arnold SF, Obourn JD, Jaffe H and Notides AC: Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J Steroid Biochem Mol Biol 55(2): 163-172, 1995.
66. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J and Lannigan DA: pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18(4): 1978-1984, 1998.
67. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ: Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61(16): 5985-5991, 2001.
68. Nicholson RI, McClelland RA, Robertson JF and Gee JM: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6(3): 373-387, 1999.
69. Petz LN, Ziegler YS, Schultz JR and Nardulli AM: Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 18(3): 521-532, 2004.
70. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(75): 9817-9824, 2001.
71. DeGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW and Weiss GR: NF-kappaB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15(6): 885-890, 2004.
72. Faridi J, Wang L, Endemann G and Roth RA: Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9(8): 2933-2939, 2003.
73. Guillonneau X, Bryckaert M, Launay-Longo C, Courtois Y and Mascarelli F: Endogenous FGF1-induced activation and synthesis of extracellular signal-regulated kinase 2 reduce cell apoptosis in retinal-pigmented epithelial cells. J Biol Chem 273(15): 22367-22373, 1998.
74. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I and Fuks Z: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54(10): 2591-2597, 1994.
75. Ray P, Devaux Y, Stolz DB, Yarlagadda M, Watkins SC, Lu Y, Chen L, Yang XF and Ray A: Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci USA 100(10): 6098-6103, 2003.
76. 3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 50(1): 15-26, 2002.
77. Fehrenbach H, Kasper M, Koslowski R, Pan T, Schuh D, Muller M and Mason RJ: Alveolar epithelial type II cell apoptosis in vivo during resolution of keratinocyte growth factor-induced hyperplasia in the rat. Histochem Cell Biol 114(1): 49-61, 2000.
78. Panos RJ, Bak PM, Simonet WS, Rubin JS and Smith LJ: Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest 96(4): 2026-2033, 1995.
79. Yi ES, Shabaik AS, Lacey DL, Bedoya AA, Yin S, Housley RM, Danilenko DM, Benson W, Cohen AM, Pierce GF et al: Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol 154(4): 1566-1570, 1995.
80. Kim PJ, Sakaguchi K, Sakamoto H, Saxinger C, Day R, McPhie P, Rubin JS and Bottaro DP: Colocalization of heparin and receptor binding sites on keratinocyte growth factor. Biochemistry 37(25): 8853-8862, 1998.
81. Ron D, Bottaro DP, Finch PW, Morris D, Rubin JS and Aaronson SA: Expression of biologically active recombinant keratinocyte growth factor. Structure/function analysis of amino-terminal truncation mutants. J Biol Chem 268(4): 2984-2988, 1993.
82. Canatan H, Shidaifat F, Kulp SK, Zhang Y, Chang WY, Brueggemeir RW and Lin YC: Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells. Endocr Res 23(4): 311-323, 1997.
83. Zhang Y, Kulp SK, Sugimoto Y, Farrar WB, Brueggemeier RW and Lin YC: Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Res 18(4A): 2541-2546, 1998.